TO THE EDITOR: Dorn et al. have described a dosimetryguided approach for calculating the
largest “safe” dose of 131I for treatment of differentiated thyroid cancer (1). With this method …

Thyroid stunning is usually defined as decreased uptake or trapping of radioiodine 131I by
normal thyroid tissue or differentiated thyroid cancer after diagnostic administration of 131I …

TO THE EDITOR: We read with interest the article by Yeung et al.(1) on therapeutic
radioiodine uptake in thyroid remnants after tracer dosimetry. The authors reported …

Radio-iodine therapy for thyroid carcinoma has been given for many years but its use
remains surrounded with controversies. Should patients routinely have thyroid remnants …

TO THE EDITOR: We read with interest the article by Yeung et al.(1) on therapeutic
radioiodine uptake in thyroid remnants after tracer dosimetry. The authors reported …

With regard to the treatment of differentiated non-medullary thyroid carcinoma, there is
controversy over whether radiation from a diagnostic radioiodine (131 I) application really …

I read with interest the paper by Sabri et al.[1]. In patients given two-step radioiodine therapy
for benign thyroid disease, they quantified 32% lower mean thyroid uptake after 435±232 …

TO THE EDITOR: We read with interest the article by Deandreis et al.(1) that compared a
fixed-activity approach to radioiodine treatment of metastatic differentiated thyroid cancer …

Stunning of thyroid tissue by diagnostic activities of 131I has been described by some
investigators and refuted by others. The support both for and against stunning has at times …

TO THE EDITOR: From their study of patients referred for radioiodine ablation, Cholewinski
et al.(1) concluded that diagnostic whole-body scanning can be performed effectively with a …